Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Thurman

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Bioinformatics (Oxford, England)|June 18, 2005
Predicting the in vivo signature of human gene regulatory sequencesWilliam Stafford Noble, Scott Kuehn, Robert Thurman, et al.
Bioinformatics (Oxford, England)|July 2, 2008
Automated mapping of large-scale chromatin structure in ENCODEHeng Lian, William A Thompson, Robert Thurman, et al.
Nature|February 20, 2015
Cell-of-origin chromatin organization shapes the mutational landscape of cancerPaz Polak, Rosa Karlić, Amnon Koren, et al.
Cancer Research Communications|September 18, 2023
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast CancerDevra Olson, Janelle Taylor, Kelsi Willis, et al.
Molecular Cancer Therapeutics|September 29, 2023
Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor ImmunityRyan A Heiser, Anthony T Cao, Weiping Zeng, et al.
Epigenetics & Chromatin|May 15, 2015
DNase I hypersensitivity analysis of the mouse brain and retina identifies region-specific regulatory elementsMatthew S Wilken, Joseph A Brzezinski, Anna La Torre, et al.
Nature Methods|June 23, 2006
Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarraysPeter J Sabo, Michael S Kuehn, Robert Thurman, et al.
Molecular Cancer Therapeutics|February 17, 2023
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor ModelsRebecca Mazahreh, Marsha L Mason, John J Gosink, et al.
Journal for Immunotherapy of Cancer|October 4, 2023
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical modelsElizabeth Gray, Michelle Ulrich, Angela Epp, et al.
Nature|April 18, 2014
Domains of genome-wide gene expression dysregulation in Down's syndromeAudrey Letourneau, Federico A Santoni, Ximena Bonilla, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Bioinformatics (Oxford, England)|June 18, 2005
Predicting the in vivo signature of human gene regulatory sequencesWilliam Stafford Noble, Scott Kuehn, Robert Thurman, et al.
Bioinformatics (Oxford, England)|July 2, 2008
Automated mapping of large-scale chromatin structure in ENCODEHeng Lian, William A Thompson, Robert Thurman, et al.
Nature|February 20, 2015
Cell-of-origin chromatin organization shapes the mutational landscape of cancerPaz Polak, Rosa Karlić, Amnon Koren, et al.
Cancer Research Communications|September 18, 2023
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast CancerDevra Olson, Janelle Taylor, Kelsi Willis, et al.
Molecular Cancer Therapeutics|September 29, 2023
Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor ImmunityRyan A Heiser, Anthony T Cao, Weiping Zeng, et al.
Epigenetics & Chromatin|May 15, 2015
DNase I hypersensitivity analysis of the mouse brain and retina identifies region-specific regulatory elementsMatthew S Wilken, Joseph A Brzezinski, Anna La Torre, et al.
Nature Methods|June 23, 2006
Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarraysPeter J Sabo, Michael S Kuehn, Robert Thurman, et al.
Molecular Cancer Therapeutics|February 17, 2023
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor ModelsRebecca Mazahreh, Marsha L Mason, John J Gosink, et al.
Journal for Immunotherapy of Cancer|October 4, 2023
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical modelsElizabeth Gray, Michelle Ulrich, Angela Epp, et al.
Nature|April 18, 2014
Domains of genome-wide gene expression dysregulation in Down's syndromeAudrey Letourneau, Federico A Santoni, Ximena Bonilla, et al.
Pageof 1